ライフサイエンスコーパス: sexual dysfunction

1 h medical and public discourse about 'Female Sexual Dysfunction'.

2 urvivors (BCSs) with a DSM-IV diagnosis of a sexual dysfunction.

3 ter cope with their posttreatment urinary or sexual dysfunction.

4 uch as bladder stones, increased the rate of sexual dysfunction.

5 lationships and masculinity, which accompany sexual dysfunction.

6 including hot flashes, vaginal dryness, and sexual dysfunction.

7 suggested a causal relation between BPH and sexual dysfunction.

8 nd only small increased risks of fatigue and sexual dysfunction.

9 on with symptoms of depression, fatigue, and sexual dysfunction.

10 ntial roles as therapeutic agents for female sexual dysfunction.

11 evelop appropriate management strategies for sexual dysfunction.

12 mining the pharmacological aspects of female sexual dysfunction.

13 bo in ameliorating antidepressant-associated sexual dysfunction.

14 gs in the evaluation and treatment of female sexual dysfunction.

15 ial groups demonstrate different patterns of sexual dysfunction.

16 the adjuvant setting experienced symptoms of sexual dysfunction.

17 ated complications, including, unexpectedly, sexual dysfunction.

18 al sexual differentiation and any associated sexual dysfunction.

19 ty-of-life impairment, including itching and sexual dysfunction.

20 ention that was implemented to alleviate the sexual dysfunction.

21 en do not receive adequate support to manage sexual dysfunction.

22 e link between metabolic syndrome (MetS) and sexual dysfunction.

23 emerged pointing to a relationship with male sexual dysfunction.

24 n and urinary tract erosion, thigh pain, and sexual dysfunction.

25 tions in testosterone truly account for male sexual dysfunction.

26 ypogonadism and its correlation with QoL and sexual dysfunction.

27 to be associated with increased urinary and sexual dysfunction.

28 e baseline function had similar increases in sexual dysfunction.

29 l in the evaluation and treatment outcome of sexual dysfunction.

30 itted by SRIs but who were also experiencing sexual dysfunction.

31 brief sexual counseling can often alleviate sexual dysfunction.

32 obesity, cancer, cardiovascular disease and sexual dysfunction.

33 g with treatment-related urinary, bowel, and sexual dysfunction.

34 symptom in men with CP/CPPS as it relates to sexual dysfunction.

35 fects older men and is often associated with sexual dysfunction.

36 used to identify factors associated with the sexual dysfunction.

37 nderlying the link between LUTS/BPH and male sexual dysfunction.

38 mage, and menopausal symptoms in BCSs with a sexual dysfunction.

39 ed for the association between LUTS and male sexual dysfunction.

40 rofiles, and signs of prolactin elevation or sexual dysfunction.

41 f attempted suicide, child abuse, and recent sexual dysfunction.

42 d mean baseline scores were 41.8 to 46.4 for sexual dysfunction, 20.8 to 22.8 for urinary obstruction

43 nificant annual increase in risk of reported sexual dysfunction (5 per 1000 patients; 95% CI, 2-8), e

44 problems (7.7 [7.8] vs 7.9 [9.1]; P = .70), sexual dysfunction (68.2 [34.6] vs 65.9 [34.7]; P = .65)

45 Urinary and sexual dysfunctions affecting quality of life were asses

46 Sexual dysfunction after radiotherapy increased less but

47 determined potential confounding factors of sexual dysfunction: age; disease duration; physical disa

48 tures, myocardial infarction, and markers of sexual dysfunction, although there are few studies for e

49 1% of patients reported severe problems with sexual dysfunction and 11.9% with abdominal pain.

50 opriate screening, information, and support, sexual dysfunction and accompanying distress can be sign

51 With increasing age, sexual dysfunction and BPH become more prevalent.

52 consistent finding is a correlation between sexual dysfunction and depression.

53 es, mutations reducing fertility may lead to sexual dysfunction and even the loss of sex.

54 Previously reported associations between sexual dysfunction and hypertension, diabetes, and depre

55 henotypes in this syndrome, such as obesity, sexual dysfunction and possibly sleep abnormalities.

56 This review explores the links between sexual dysfunction and prostatitis.

57 mpare higher doses of bupropion for treating sexual dysfunction and should include a greater number o

58 ata from individual studies showed that male sexual dysfunction and urinary dysfunction (three studie

59 Greater sexual dysfunction and urinary incontinence occur in the

60 reported on depressive symptoms, fatigue, or sexual dysfunction and were selected for inclusion.

61 bladder irritability, by increasingly severe sexual dysfunction and, in men aged more than 65 years,

62 substantial increase in menopausal symptoms, sexual dysfunction, and diminished quality of life.

63 ween primary treatment, urinary dysfunction, sexual dysfunction, and general health-related quality o

64 effective procedure, with low morbidity, no sexual dysfunction, and good short- and intermediate-ter

65 th adverse birth outcomes, hyperandrogenism, sexual dysfunction, and impaired implantation in humans,

66 apeutic indications, including inflammation, sexual dysfunction, and obesity.

67 studies of combination therapy for LUTS/BPH, sexual dysfunction, and other age-associated comorbiditi

68 er importance on procedure-related bleeding, sexual dysfunction, and perforation.

69 ence, cognitive changes, somatic complaints, sexual dysfunction, and reduced quality of life may be s

70 xercise training, fatigue, bowel/bladder and sexual dysfunction, and sleep disruption.

71 sculine self-esteem and little distress from sexual dysfunction, and were married.

72 erectile dysfunction, epidemiologic data on sexual dysfunction are relatively scant for both women a

73 Urinary and sexual dysfunctions are recognized complications of rect

74 as chronic diarrhea, dizziness, fatigue, and sexual dysfunction, are due to cholinergic autonomic dys

75 uate discrimination on 4 of the 5 domains of sexual dysfunction (area under the receiver operating ch

76 east 6 weeks, who were euthymic, and who had sexual dysfunction as determined by a total score greate

77 buspirone and amantadine in the treatment of sexual dysfunction associated with fluoxetine administra

78 other aspects of sexual function in men with sexual dysfunction associated with the use of SRI antide

79 amelioration of, the hyperprolactinemia and sexual dysfunction associated with these drugs.

80 atients reported greater urinary, bowel, and sexual dysfunction, but similar health status.

81 The risk of sexual dysfunction can be quantified preoperatively usin

82 yndromes that are reported after HCT include sexual dysfunction, cognitive problems, fatigue, insomni

83 mic and thrombotic events, endocrine events, sexual dysfunction, dementia, and depression.

84 The effect of sexual dysfunction deteriorated with age (odds ratio for

85 another paraphilia diagnosis, and 24% for a sexual dysfunction diagnosis.

86 ptors as possible treatments for obesity and sexual dysfunction due to the role of these receptors in

87 he route of administration, risk of fatigue, sexual dysfunction, dysphagia, shortness of breath and/o

88 en appear slightly more likely to experience sexual dysfunctions, especially later in life.

89 Female sexual dysfunction (FSD) is an important but controversi

90 Profound sexual dysfunction has been shown to have a significant

91 In women, sexual dysfunction has not been associated with serum te

92 ease associated pelvic pain; infertility and sexual dysfunction have a significant adverse clinical,

93 tion in women with antidepressant-associated sexual dysfunction have been reported, and there is unce

94 ng an integrative treatment model to address sexual dysfunction in a cancer survivorship treatment se

95 LUTS/BPH is an independent risk factor for sexual dysfunction in aging men.

96 luate the hypothesis that fluoxetine-induced sexual dysfunction in female rats derived from disruptio

97 arizes current knowledge about the nature of sexual dysfunction in gynecological cancers, highlightin

98 nesis, testosterone deficiency, and physical sexual dysfunction in male pubertal, adolescent, and you

99 aires have lead to a better understanding of sexual dysfunction in men.

100 e is a potential target for the treatment of sexual dysfunction in the male.

101 is study population, sildenafil treatment of sexual dysfunction in women taking SRIs was associated w

102 rmacological approaches to the management of sexual dysfunction in women.

103 tions of female sexual problems, and 'Female Sexual Dysfunction' in particular, throughout the 20th c

104 Hormonal imbalances may contribute to sexual dysfunction, in particular sexual arousal disorde

105 depending upon their age, have complaints of sexual dysfunction, including decreased libido, vaginal

106 Sexual dysfunction increased in all patients, particular

107 Sexual dysfunction increased steadily over the study per

108 cts of the SSRI fluoxetine, and reversed the sexual dysfunction induced by chronic fluoxetine treatme

109 sustained-release bupropion with placebo for sexual dysfunction induced by selective serotonin reupta

110 idimensional Fatigue Inventory), bladder and sexual dysfunction (International Prostate Symptom Score

111 Sexual dysfunction is a common adverse effect of antidep

112 Antidepressant-associated sexual dysfunction is a common adverse effect that frequ

113 Sexual dysfunction is a common clinical symptom in women

114 In summary, sexual dysfunction is a common finding in both men and w

115 Female sexual dysfunction is a common, multifactorial medical c

116 Female sexual dysfunction is a significant problem that affects

117 Female sexual dysfunction is also now gaining some attention, w

118 The results indicate that sexual dysfunction is an important public health concern

119 Sexual dysfunction is common among women with schizophre

120 Moreover, sexual dysfunction is highly associated with negative ex

121 Experience of sexual dysfunction is more likely among women and men wi

122 Sexual dysfunction is more prevalent for women (43%) tha

123 l risks of depressive symptoms, fatigue, and sexual dysfunction is not supported by data from clinica

124 Sexual dysfunction is one of the most common and distres

125 n treatment of BPH (or watchful waiting) and sexual dysfunction is usually coincidental, unless sympt

126 development of behavioral problems, such as sexual dysfunction, later in life.

127 Sexual dysfunction like ejaculation discomfort is descri

128 l sexual maturation, idiopathic infertility, sexual dysfunction, low serum testosterone concentration

129 e frequently interrupts sexual function, and sexual dysfunction may signal serious endocrine disease.

130 , 30-day mortality, bladder dysfunction, and sexual dysfunction, none showed a statistically signific

131 Vasomotor symptoms and sexual dysfunction occur frequently in women who have an

132 Sexual dysfunction occurred in 18% of patients and was p

133 Sexual dysfunction occurred more frequently in women who

134 r comorbidities, and 17 to avoid the risk of sexual dysfunction or infertility.

135 s, digoxin and thiazide diuretics may worsen sexual dysfunction owing to medication side effects.

136 Owing to the link between LUTS/BPH and male sexual dysfunction, patients presenting with one of thes

137 rols, each therapy group reported bothersome sexual dysfunction; radical prostatectomy was associated

138 ndomized studies exist to guide treatment of sexual dysfunction related to MetS; rather, most studies

139 Thus, despite some recovery, sexual dysfunction remained a major problem for men and

140 ng innervation, are reflected in the urinary/sexual dysfunction's in aged animals.

141 Compared with active surveillance, mean sexual dysfunction scores worsened by 3 months for patie

142 Chronic pain is often associated with sexual dysfunction, suggesting that pain can reduce libi

143 Men who never smoked reported less sexual dysfunction than did those who either had quit or

144 lantation, women reported significantly more sexual dysfunction than men.

145 ded about key risk factors and predictors of sexual dysfunction that can be used to guide appropriate

146 adverse effects such as urinary symptoms and sexual dysfunction that can negatively affect quality of

147 For sexual dysfunction, the models in the two samples explai

148 thematical model for quantifying the risk of sexual dysfunction through time for this group of patien

149 The instrument contains 4 domains-sexual dysfunction, urinary obstruction and irritation,

150 Treatment of bowel, bladder and sexual dysfunction utilizing a variety of modalities has

151 tion after 12 months, but the time course of sexual dysfunction varied by treatment and, for bowel fu

152 ntributions of chemotherapy and tamoxifen to sexual dysfunction warrant prospective study.

153 Transient sexual dysfunction was noted in 3 of 14 patients, but no

154 Urinary, bowel, and sexual dysfunction were assessed with symptom indexes; h

155 Bowel and sexual dysfunction were associated with poorer sexual in

156 Urinary incontinence and erectile and sexual dysfunction were each greater with surgery than w

157 Vaginal atrophy, sexual interest, and sexual dysfunction were improved.

158 primary treatment, urinary dysfunction, and sexual dysfunction were independently associated with ge

159 OFS results in more menopausal symptoms and sexual dysfunction, which contributes to inferior self-r

160 dence of an association between LUTS/BPH and sexual dysfunction will be reviewed, as well as the effe

161 logists are benign prostatic hyperplasia and sexual dysfunction, with an increasing number of patient